SOUTH SAN FRANCISCO, Calif., Oct. 15, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that data from a preclinical study of ZYBRESTAT® (fosbretabulin tromethamine/combretastatin A-4 phosphate or CA4P) demonstrating antitumor activity in a model of pancreatic neuroendocrine tumors (PNETs) will be presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, being held in the Hynes Convention Center, Boston, MA, October 19-23, 2013.
Help employers find you! Check out all the jobs and post your resume.
